October 29, 2025 - Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular ...

October 30, 2025 - (PRESS RELEASE) LYON, 29-Oct-2025 — /EuropaWire/ — BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, ...

November 17, 2025 - Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular pertussis vaccine.

Biotech, Business of Medicine, ... News Leave a comment · LYON, 29-Oct-2025 — /EuropaWire/ — BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and ...

October 30, 2025 - The certification allows BioNet to produce its acellular pertussis vaccine in compliance with the European Union’s high-level quality and safety requirements. The approval follows an inspection conducted by Ireland’s Health Products Regulatory Authority (HPRA), which verified that BioNet’s production site adheres to the EU’s strict criteria for manufacturing excellence and regulatory compliance. This achievement marks a significant step in the company’s ongoing efforts to gain European Medicines Agency (EMA) approval for its recombinant acellular pertussis vaccine candidate, known as VacPertagen.

November 20, 2025 - BioNet is operating in 25 countries with a direct presence in Europe and Asia-Pacific. BioNet recently achieved EU-GMP certification for its pertussis vaccine manufacturing facility, following inspection and approval by the Health Products Regulatory Authority (HPRA) of Ireland.

BioNet, Bangkok. 521 likes · 6 talking about this · 83 were here. BioNet is a pioneering biotechnology group that specialises in the development of next-generation vaccines.

November 21, 2025 - BioNet is operating in 25 countries with a direct presence in Europe and Asia-Pacific. BioNet recently achieved EU-GMP certification for its pertussis vaccine manufacturing facility, following inspection and approval by the Health Products Regulatory Authority (HPRA) of Ireland.

“This milestone underscores BioNet’s resolute dedication to world-class manufacturing standards and marks a key step in the ongoing centralized regulatory review of its recombinant acellular pertussis vaccine candidate, VacPertagen, by the European Medicines Agency (EMA).” said Philippe Guillot-Chêne, CEO, BioNet in Europe. The EU-GMP certification confirms that BioNet’s facilities, quality systems and quality controls meet the highest international criteria.

September 20, 2024 - BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis November 21, 2025 · BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing November 17, 2025

January 15, 2026 - Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular pertussis vaccine.

March 20, 2023 - “This milestone underscores BioNet’s resolute dedication to world-class manufacturing standards and marks a key step in the ongoing centralized regulatory review of its recombinant acellular pertussis vaccine candidate, VacPertagen, by the European Medicines Agency (EMA).” said Philippe Guillot-Chêne, CEO, BioNet in Europe. The EU-GMP certification confirms that BioNet’s facilities, quality systems and quality controls meet the highest international criteria.

October 30, 2025 - The EMA review is ongoing; as part of that process BioNet achieved a key regulatory milestone in October 2025 when it received EU Good Manufacturing Practice (EU-GMP) certification for its pertussis vaccine production.

May 19, 2023 - “This milestone underscores BioNet’s resolute dedication to world-class manufacturing standards and marks a key step in the ongoing centralized regulatory review of its recombinant acellular pertussis vaccine candidate, VacPertagen, by the European Medicines Agency (EMA).” said Philippe Guillot-Chêne, CEO, BioNet in Europe. The EU-GMP certification confirms that BioNet’s facilities, quality systems and quality controls meet the highest international criteria.

BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.

November 19, 2025 - 18, 2025 /PRNewswire/ -- BioNet, a biotechnology company focused on next-generation vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for VacPertagen, a standalone acellular pertussis vaccine.

November 21, 2025 - BioNet recently achieved EU-GMP certification for its pertussis vaccine manufacturing facility, following inspection and approval by the Health Products Regulatory Authority (HPRA) of Ireland.

Drawing on its expertise in translational research, BioNet has become the leading producer of recombinant pertussis vaccines and has recently demonstrated its excellence by obtaining EU GMP certification.

January 15, 2026 - The approval marks VacPertagen as the first and only standalone pertussis vaccine on the market. VacPertagen has been engineered to target the toxin that is responsible for severe pertussis disease symptoms (pertussis toxin) with strong neutralising responses.

We lead in the development of recombinant acellular pertussis vaccines using PTgen – a genetically detoxified pertussis toxin that preserves the native protein structure for stronger, longer-lasting immunity.